封面
市场调查报告书
商品编码
1771715

美国伴侣动物心臟药物市场规模、份额、趋势分析报告:按药物、动物类型、适应症、最终用途、分销管道、细分预测,2025-2033

U.S. Companion Animal Cardiac Pharmaceuticals Market Size, Share & Trends Analysis Report By Pharmaceuticals, By Animals Type (Dogs, Cats, Horses), By Indication, By End Use, By Distribution Channel, And Segment Forecasts, 2025 - 2033

出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势:

美国伴侣动物心臟药物市场规模预计在 2024 年为 7.7629 亿美元,预计到 2033 年将达到 14.9952 亿美元,2025 年至 2033 年的复合年增长率为 7.76%。推动市场发展的关键因素包括宠物心臟病患病率上升、宠物医疗费用增加以及研发投入增加。

例如,根据 Small Door Inc. 发表的报导,郁血性心臟衰竭衰竭(CHF) 在狗中比较常见,影响大约 10% 的所有狗和大约 75% 患有某种心臟病的老年狗。

伴侣动物心臟病盛行率的不断上升,正成为兽医心臟病服务扩张的关键驱动力。由于兽医护理、营养和生活方式的改善,宠物寿命延长,它们也更容易患上心血管疾病等与老龄化相关的慢性疾病。兽医越来越多地诊断需要专业知识和治疗的疾病,例如瓣膜疾病、心肌病和心律不整。

近年来,兽医循环系统取得了长足进步,彻底改变了我们诊断和治疗动物心臟病的方式。诊断工具、手术技术和治疗方法的创新提高了护理的精准度,改善了宠物的治疗效果和生活品质。例如,2025年4月,奥本大学兽医学院为一隻名叫Hash Brown的小猫进行了一项开创性的手术,它患有上颚窦狭窄。这项混合球囊瓣环成形是世界上首例针对如此小的婴儿患者进行的手术,由一个专家团队通力合作完成。

创新治疗方法的兴起以及人们对宠物心臟健康重要性的日益重视,推动了兽医心臟病学行业的发展。宠物饲主意识到,曾经只有人类才能获得的延长生命疗法如今已可行,因此他们正在为自己的宠物寻求专业的护理。因此,对先进兽医循环系统服务的需求预计将持续增长,并进一步巩固其作为现代兽医学重要组成部分的地位。

例如,2024年6月,印度农业研究理事会发表了一项研究,调查了2022年7月至2023年9月14个月期间435只有全身性疾病史的狗的心律不整发生率。此评估旨在检视心律不整的发生情况,其中114隻(26.21%)狗表现出各种类型的心律不整,包括心房颤动(30.70%)、ST段覆盖、窦性停搏(各9.65%)和ST段抬高(各8.77%)。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国伴侣动物心臟药物市场的趋势与展望

  • 市场展望
    • 母市场
    • 补贴市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国伴侣动物心臟药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 法律规范
    • 定价分析
    • 宠物主人人口统计
    • 2024 年按国家和物种分類的宠物数量估计

第四章美国伴侣动物心臟药物市场:药物估计与趋势分析

  • 细分仪表板
  • 美国伴侣动物心臟药物市场:药物变异分析
  • 美国伴侣动物心臟药物市场规模及趋势分析(依药物,2021-2033)
  • 匹莫苯丹
  • Spiranolactone和盐酸Benazepril
  • 其他的

第五章美国伴侣动物心臟药物市场:按动物类型进行的估计和趋势分析

  • 细分仪表板
  • 美国伴侣动物心臟药物市场:按动物类型分類的差异分析
  • 美国伴侣动物心臟药物市场规模及趋势分析(以动物类型),2021-2033 年
  • 其他的

第六章美国伴侣动物心臟药物市场:适应症估计与趋势分析

  • 细分仪表板
  • 美国伴侣动物心臟药物市场:适应症变化分析
  • 美国伴侣动物心臟药物市场规模及趋势分析(依适应症)(2021-2033)
  • 郁血性心臟衰竭衰竭
  • 心肌疾病
  • 心律不整
  • 其他的

第七章美国伴侣动物心臟药物市场:最终用途估计和趋势分析

  • 细分仪表板
  • 美国伴侣动物心臟药物市场:最终用途差异分析
  • 美国伴侣动物心臟药物市场规模及趋势分析(依最终用途),2021-2033 年
    • 兽医诊所
    • 其他的

第八章美国伴侣动物心臟药物市场:通路评估与趋势分析

  • 细分仪表板
  • 美国伴侣动物心臟药物市场:通路变化分析
  • 美国伴侣动物心臟药物市场规模及趋势分析(按分销管道),2021-2033 年
    • 医院/诊所药房
    • 零售
    • 电子商务

第九章 竞争态势

  • 市场参与企业分类
  • 企业市场分析/堆图分析
  • 公司简介
    • Zoetis
    • Boehringer Ingelheim International Gmbh
    • Elanco
    • Merck &Co., Inc.
    • Dechra Pharmaceuticals PLC
    • Ceva Sante Animale
    • Phibro Animal Health Corporation
    • Virbac
    • Bimeda Corporate
    • Biogenesis Bago
  • 战略地图
    • 合併与收购
    • 伙伴关係和合作
    • 应用程式启动
    • 其他的
  • 其他主要角色列表
Product Code: GVR-4-68040-635-6

Market Size & Trends:

The U.S. companion animal cardiac pharmaceuticals market size was estimated at USD 776.29 million in 2024 and is projected reach USD 1,499.52 million by 2033, growing at a CAGR of 7.76% from 2025 to 2033. The key factors responsible for driving the market growth include the rising incidence of heart diseases in pets, increasing pet health expenditure, and increasing research and development.

For instance, according to an article published by Small Door Inc., Congestive heart failure (CHF) is relatively prevalent in dogs, affecting around 10% of the overall canine population and as many as 75% of older dogs who suffer from some form of heart disease.

The growing incidence of heart disease among companion animals is becoming a key driver in expanding veterinary cardiology services. As pets live longer due to general veterinary care, nutrition, and lifestyle improvements, they are more likely to develop chronic age-related conditions such as cardiovascular diseases. Veterinarians are increasingly diagnosing conditions such as valvular diseases, cardiomyopathies, and arrhythmias, which require specialized knowledge and treatment.

Veterinary cardiology has witnessed significant advancements in recent years, transforming how heart conditions in animals are diagnosed and treated. Innovations in diagnostic tools, surgical techniques, and therapeutic options are enhancing the precision of care and improving the outcomes and quality of life for pets. For instance, in April 2025, Auburn University's College of Veterinary Medicine performed a groundbreaking surgery on Hashbrown, a kitten with supravalvular mitral stenosis. This hybrid balloon valvuloplasty, a first-of-its-kind procedure for such a small and young patient, involved a collaborative effort by professionals.

The rise in innovative treatments and the increasing awareness of the importance of heart health in pets is driving growth in the veterinary cardiology industry. Pet owners increasingly seek specialized care for their animals, recognizing the availability of life-extending treatments that were once only accessible to humans. As a result, the demand for advanced veterinary cardiology services is expected to grow, further solidifying its place as a crucial component of modern veterinary medicine.

For example, in June 2024, the Indian Council for Agricultural Research published a study examining the incidence of cardiac arrhythmias in 435 dogs with a history of generalized diseases over 14 months from July 2022 to September 2023. The assessment was aimed to determine the occurrence of arrhythmias and found that 114 dogs (26.21%) displayed various types, including atrial fibrillation (30.70%), ST-segment coving, sinus arrest (9.65% each), and ST-segment elevation (8.77% each).

U.S. Companion Animal Cardiac Pharmaceuticals Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal cardiac pharmaceuticals market report based on pharmaceuticals, animal type, indication, end use, and distribution channel.

  • Pharmaceuticals Outlook (Revenue, USD Million, 2021 - 2033)
  • Pimobendan
  • Spironolactone and Benazepril Hydrochloride
  • Others
  • Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Dogs
  • Cats
  • Horses
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Congestive Heart Failure
  • Myocardial (Heart Muscle) Disease
  • Arrhythmias
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Hospitals & Clinics
  • Others
  • Distribution Channel (Revenue, USD Million, 2021 - 2033)
  • Hospital/ Clinic Pharmacy
  • Retail
  • E-Commerce

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Cardiac Pharmaceuticals Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of heart diseases in pets
      • 3.2.1.2. Advancements in veterinary medicine
      • 3.2.1.3. Increasing research & development
      • 3.2.1.4. Increasing adoption of pet insurance
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of treatment
      • 3.2.2.2. Lack of skilled professionals
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Pet ownership Demographics
    • 3.3.6. Estimated pet Population by key countries, key species, 2024

Chapter 4. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Movement Analysis
  • 4.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by pharmaceuticals, 2021 to 2033 (USD Million)
  • 4.4. Pimobendan
    • 4.4.1. Pimobendan Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Spironolactone and benazepril hydrochloride
    • 4.5.1. Spironolactone and benazepril hydrochloride Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal type Movement Analysis
  • 5.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Animal type, 2021 to 2033 (USD Million)
  • 5.4. Dogs
    • 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cats
    • 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Horses
    • 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Movement Analysis
  • 6.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.4. Congestive Heart Failure
    • 6.4.1. Congestive Heart Failure Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Myocardial (Heart Muscle) Disease
    • 6.5.1. Myocardial (Heart Muscle) Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Arrhythmias
    • 6.6.1. Arrhythmias Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Movement Analysis
  • 7.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by end use, 2021 to 2033 (USD Million)
    • 7.3.1. Veterinary Hospitals & Clinics
      • 7.3.1.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Others
      • 7.3.2.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Movement Analysis
  • 8.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
    • 8.3.1. Hospital/ Clinic Pharmacy
      • 8.3.1.1. Hospital/ Clinic Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Retail
      • 8.3.2.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. E-Commerce
      • 8.3.3.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Zoetis
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Boehringer Ingelheim International Gmbh
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Elanco
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Merck & Co., Inc.
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Dechra Pharmaceuticals PLC
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Ceva Sante Animale
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Phibro Animal Health Corporation
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Virbac
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Bimeda Corporate
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Biogenesis Bago
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Application launch
    • 9.4.4. Others
  • 9.5. List of other key players

List of Tables

  • Table 1 List of secondary sources
  • Table 2 U.S Companion Animal Cardiac Pharmaceuticals Market, by Pharmaceuticals, 2021 - 2033 (USD Million)
  • Table 3 U.S Companion Animal Cardiac Pharmaceuticals Market, by Animal type, 2021 - 2033 (USD Million)
  • Table 4 U.S Companion Animal Cardiac Pharmaceuticals Market, by Indication, 2021 - 2033 (USD Million)
  • Table 5 U.S Companion Animal Cardiac Pharmaceuticals Market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 U.S Companion Animal Cardiac Pharmaceuticals Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 7 Company Overview
  • Table 8 Product Benchmarking
  • Table 9 Financial Performance
  • Table 10 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Companion Animal Cardiac Pharmaceuticals Market revenue, 2021 - 2033 (USD Million)
  • Fig. 10 U.S. Companion Animal Cardiac Pharmaceuticals Market snapshot
  • Fig. 11 U.S. Companion Animal Cardiac Pharmaceuticals Market driver impact
  • Fig. 12 U.S. Companion Animal Cardiac Pharmaceuticals Market restraint impact
  • Fig. 13 U.S. Companion Animal Cardiac Pharmaceuticals key takeaways (USD Million)
  • Fig. 14 U.S. Companion Animal Cardiac Pharmaceuticals Market: pharmaceuticals movement analysis
  • Fig. 15 Pimobendan market, 2021 - 2033 (USD Million)
  • Fig. 16 Spironolactone and benazepril hydrochloride market, 2021 - 2033 (USD Million)
  • Fig. 17 Others market, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. Companion Animal Cardiac Pharmaceuticals animal type key takeaways (USD Million)
  • Fig. 19 U.S. Companion Animal Cardiac Pharmaceuticals Market: animal Type movement analysis
  • Fig. 20 Dogs market, 2021 - 2033 (USD Million)
  • Fig. 21 Cats market, 2021 - 2033 (USD Million)
  • Fig. 22 Horses market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Companion Animal Cardiac Pharmaceuticals Market Indication key takeaways (USD Million)
  • Fig. 25 U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication movement analysis
  • Fig. 26 Congestive Heart Failure market, 2021 - 2033 (USD Million)
  • Fig. 27 Myocardial (Heart Muscle) Disease market, 2021 - 2033 (USD Million)
  • Fig. 28 Arrhythmias market, 2021 - 2033 (USD Million)
  • Fig. 29 Others market, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Companion Animal Cardiac Pharmaceuticals Market End Use key takeaways (USD Million)
  • Fig. 31 U.S. Companion Animal Cardiac Pharmaceuticals Market: End use movement analysis
  • Fig. 32 Veterinary Hospitals & Clinics market, 2021 - 2033 (USD Million)
  • Fig. 33 Others market, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Companion Animal Cardiac Pharmaceuticals Market Distribution Channel key takeaways (USD Million)
  • Fig. 35 U.S. Companion Animal Cardiac Pharmaceuticals Market: Distribution Channel movement analysis
  • Fig. 36 Hospital/ Clinic Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 37 Retail market, 2021 - 2033 (USD Million)
  • Fig. 38 E-Commerce market, 2021 - 2033 (USD Million)
  • Fig. 39 Market participant categorization